O REGILIO MEGICAL PROPERTY OF THE PROPERTY OF

No. F. 4-17/2025-DD-PS-I(Adv.B-M-3)

Government of Pakistan

Drug Regulatory Authority of Pakistan

Prime Minister's National Health Complex, Park Road Islamabad

Islamabad, the 29th of July, 2025

M/s. Abbott Laboratories (Pakistan) Ltd.,
Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi
Karachi.

Subject: <u>Application for Approval to Advertise Surbex-Z Tablet (Reg. No: 010972) Through Display Media</u>

I am directed to refer to your application regarding the subject cited above and to state that the Advertisement Board in its 3rd meeting held on 4th July, 2025 has approved the advertisement of your product namely Surbex-Z Tablet (Reg. No: 010972) through following Media/Mode.

Sr # 1.	Name of Product/ Reg. No. Surbex-Z Tablet 010972	Media of Advertisement			
		i. ii. iii. iv. v. vi. vii.	Dangler Ad Billboard Ad. 1 Billboard Ad. 2 Print Ad. Print Ad. 1 Print Ad. 2 Print Ad. 3 Print Ad. 4 Poster Ad. 1	Digita i. ii. iii.	Media Mobile Ad Digital Banner Ad Digital Desktop Ad
		ix. x. xi. xii. xiii. xiv.	Poster Ad. 1 Poster Ad. 2 Pharmacy Branding Ad. 1 Pharmacy Branding Ad. 2 Pharmacy Branding Ad. 3 Counter Top Ad1		

2. The approval of advertisement(s) on Prescribed Form-II are enclosed. You are further required to submit details of the link(s) of social media handles, platform, and campaign.

Encl: As Above

(Dr Mahvash Ansari)
Deputy Director/

Secretary Advertisement Board, Drug Regulatory Authority of Pakistan



[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Dangler Ad. mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔

طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)









[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Billboard Ad. 1 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii


تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)

Secretary Advertisement Board





Surbex (2) Se Zindagi صحت مند

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex

1. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب پو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے مضر اثرات کی صورت میں املاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ 4. دوا کو لیبل پر دی گئی ہدایات کے مطابق استعمال کریں۔



ایک گولی روزانہ



[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Billboard Ad-2 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)







Surbex (رز) Se Zindagi

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



ایک گولی روزانہ

1 تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمیں اور ڈرٹی (DRAP) کو دیں۔ 4. دوا کو نشا رہ دری گئے بدایات کے مطابقہ استعمال کیں



[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Print Ad. 1 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔

.ii

طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)








Surbex المحتادة Se Zindagi

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ د.وا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈرپ (ORAP) کو دیں۔ د.وا کو لیبل پر دی گئی بدایات کے مطابق استعمال کریں۔





[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Print Ad. 2 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)

Secretary



Display Media Print Ad 2



Surbex Se Zindagi صحت مند

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex

1. تمام دوائین بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے عضر الرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریس (۱۹۸۶ کو دیں۔ 4. دوا کو لیبل پر دی گئی بدایات کے مطابق استعمال کریں۔



ایک گولی روزانہ



[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Print Ad. 3 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)

Secretary Advertisement Board 9/amaba



Display Media



Surbex (۲) Se Zindagi

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



ایک گولی روزانہ

 لمام دوائیں بچوں کی پہنچ سے دور رکھیں۔
 طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔
 دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع معلقہ کمپنی اور ڈرپ (IORAP) کو دیں۔
 کہ دوا کے لینا رہ دی گئر بدایات کے مطابق استعمال کی ں۔



[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Print Ad. 4 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)





Surbex (۲) Se Zindagi



ایک گولی روزانہ

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



1. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ 4.دوا کو لیبل پر دی گئی ہدایات کے مطابق استعمال کریں۔





[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Pharmacy Branding Ad. 1 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii


تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ Anroved advications of the contract of t .iii

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)









[See rule 3(5)]

Government of Pakistan Drug Regulatory Authority of Pakistan

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Pharmacy Branding Ad. 2 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): <u>Surbex-Z Tablet</u> Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012...
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

i. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔

ii. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔

iii. دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)

Secretary Advertisement Board





Surbex (2) Se Zindagi

Zinc 22.5mg, Vitamin E, C, **Folic Acid & B-Complex**



[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Pharmacy Branding Ad. 3 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)

Secretary Advertisement Board slamabad





Surbex Se Zindagi صحت مند

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



1. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ 4. دوا کو لیبل پر دی گئی ہدایات کے مطابق استعمال کریں۔





[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Poster Ad. 1 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)





Display Media Poster 1



Surbex Se Zindagi صحت مند

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ ۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ ۔ دوا کے استعمال سے مضر اثرات کی صورت میں ماطلاع متعلقہ کمپنی اور ڈریپ (ORAP) ، دوا کو لیبل پر دی گئی ہدایات کے مطابق استعمال کریں۔ ایک گولی روزانہ



[See rule 3(5)]

Government of Pakistan Drug Regulatory Authority of Pakistan

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Poster Ad. 2 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ Annroyad colored to the constant of the

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)





Display Media Poster 2



Surbex (۲) Se Zindagi

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



ایک گولی روزانہ

1. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے مضر الرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ 4. دوا کو لیبل پر دی گئی ہدایات کے مطابق استعمال کریں۔



[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Counter Top Ad. 1 mode(s) of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)





Counter Top

Surbex Z Acrylic Product Holder (12 Pcs.)





27.8 cm





[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Print Ad. mode of Display Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ .iii

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)





Surbex (۲) Se Zindagi

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



ایک گولی روزانہ

1. تفام دوآنین بچون کی پہنچ سے دور رکھیں۔ 2. خلیبھتنز زلادہ خزابدہو تو آنکٹر سے رجوع کریں۔ 3. دوآ اکے استعمال سے مضر اثرات کی صورت میں افغلاج متطلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ 4. دوآکو لیئرل پر دی گئی بدلیات کے مطابق استعمال کریں۔





[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

MM/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Mobile Ad. mode(s) of Digital Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed


Advertisement Board (Signatures) (Stamp)





Mobile Ad

Width: 182 x Height: 340 Pixels





[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Digital Banner Ad mode of Digital Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

.ii

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)







Surbex Se Zindagi صحت مند

Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex





ایک گولی روزانہ

۔ تمام موالیں بچوں کی پہنج سے دور رکھیں۔ 2۔ طبیعت زیادہ حزاب ہو تو ڈکٹٹر سے رجوع کریں۔ 3۔ دوا کے استعمال سے مضر اثرات کی صورت میں افلاع متعلقہ کمینی اور ڈرپپ (1947ء کو دیں۔ 4۔دوا کو لیبل پر دی گئی بدایات کے مطابق استعمال کرد





[See rule 3(5)]

Government of Pakistan **Drug Regulatory Authority of Pakistan**

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 29th July, 2025

Approval for Advertisement of Therapeutic Goods

M/s Abbott Laboratories (Pakistan) Ltd., is/are hereby permitted to advertise Surbex-Z Tablet in Digital Desktop Ad mode(s) of Digital Media for a period of two years from the date of issuance unless earlier suspended or cancelled.

Permission of Advertisement granted for (Name): Surbex-Z Tablet Registration / Enlistment No. 010972

- 1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
- 2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
- 3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
- 4. This approval is valid for a period of two years only, from the date of issuance of this approval.
- 5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood.

تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔

.ii

صحام فرامیں بہوں سے ہوئے ہے دور رہیں۔ طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔

6. Approved advertisement specimen enclosed

Advertisement Board (Signatures) (Stamp)

Secretary Advertisement Board





Desktop Ad

App: w: 1300 Pixels x h: 150 Pixels



Zinc 22.5mg, Vitamin E, C, Folic Acid & B-Complex



ایک گولی روزانہ

المترمين وينجي بريين 2 حصة بلاه ولاين و 1 الرمونولي. 9 مال فنصل برعم فقد لباد و مدين من بناة بنيد البري الما الومن الما لي تعالى المنظر في عمد لباد لرمين من المناطقة المنظم المناطقة المنطقة المنظم المنطقة ا

Abbott

